Kornimate/medical-research-clean huggingface dataset:
bucy+vp-16 vs bucy conditioning regimen for dlbcl undergoing auto-hsct

Conditions: Autologous Hematopoietic Stem Cell Transplantation; Diffuse Large B-cell Lymphoma; Conditioning

Summary: the purpose of this study is to evaluate the safety and efficacy of bucy+vp-16 and bucy myeloablative conditioning regimens in diffuse large b-cell lymphoma undergoing autologous hematopoietic stem cell transplantation.

autologous hematopoietic stem cell transplantation (auto-hsct) is an effective therapy for diffuse large b-cell lymphoma (dlbcl).bucy conditioning regimen is a conventional scheme for dlbcl patients undergoing auto-hsct, but it has a high relapse rate. etoposide (vp-16) is extensively used in chemotherapy regimen for refractory/relapsed lymphoma. whether addition of vp-16 could reduce the relapse rate remains unclear.in this study, the safety and efficacy of bucy+vp-16 and bucy myeloablative conditioning regimens in dlbcl undergoing auto-hsct are evaluated.

Eligibility criteria:
inclusion criteria: * diffuse large b-cell lymphoma patients * achieving cr or pr after four cycles of chemotherapy, then mobilizing and collecting of peripheral blood stem cells and receiving one cycle of chemotherapy exclusion criteria: * any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure) * patients with any conditions not suitable for the trial (investigators' decision
cooling strategies for older adults in the heat

Conditions: Aging

Summary: the earth's climate is warming, and the number of heat waves has increased in recent years. at the same time, the number of adults over the age of 65 is growing. humans sweat and increase blood flow to the skin to cool their body when they get hot. older adults do not do this as well as young adults. this makes it harder to safely be in warm and/or humid conditions. it is important to learn about cooling strategies for older adults to safely be in warm and/or humid conditions. there is compelling evidence that intermittent hand and forearm cold-water immersion effectively reduces the rise of core temperature during heat stress in older adults. however, it is still unknown if this is an effective cooling strategy for older adults. furthermore, our laboratory has shown that folic acid supplementation improves blood flow responses in older adults. this may be beneficial to older adults during heat stress.

subjects sign an informed consent form and undergo a medical screening prior to participation. the screening includes a physical exam, anthropometry, chemical and lipid profiles. subjects participate in 4 experimental trials, 2 while on folic acid supplementation and 2 while on placebo. the order of treatment (folic acid supplementation or placebo) is randomized. participants will place their hands and forearms in cold tap water intermittently for one of the two trials for each treatment. the order of the hand and forearm immersion trial is randomized for each treatment. the trials are separated by at least five days. for each experiment, core temperature, heart rate, blood pressure, skin temperature, and sweat rate are measured. each experimental visit will last 2 hours.

Eligibility criteria:
inclusion criteria: * adults aged 65 and older * english proficiency exclusion criteria: * chron's disease, diverticulitis, or similar gastrointestinal disease * abnormal resting exercise electrocardiogram (ecg) * tobacco use * high-risk determined by the atherosclerotic cardiovascular disease (cvd) risk factor assessment * antiepileptic or antiseizure medications * methotrexate

Keywords: aging thermoregulation heat stress
acceptance-based care for child eating and physical activity treatment

Conditions: Pediatric Obesity; Executive Function; Self-Regulation

Summary: the purpose of this study is to develop and pilot test a new type of patient-centered, family-based treatment for children aged 8-12 with obesity and their caregivers. the treatment will focus specifically on improving children's self-regulation (sr) skills to help them better manage their feelings, behaviors, and thoughts to help them live a healthier lifestyle.

we aim to: (1) to determine the treatment needs of children ages 8-12 with obesity and their families with a focus on understanding cognitive function challenges that are related to self-regulation (using focus groups i.e. fg and feedback sessions i.e. fb). (2) to evaluate the feasibility and acceptability of this novel family-based treatment. (3) explore potential associations between pediatric cardiovascular (cvd) risk factors and self-regulation in children with and without overweight or obesity. (4) to refine the f-abt protocol and to maximize participant feasibility, acceptability, safety, and tolerability of f-abt. (5) to provide pilot, proof-of-concept, and preliminary efficacy data of beneficial effects of f-abt on sr and bmi in children with sr deficits and their caregivers.

Eligibility criteria:
inclusion criteria: - children who: (1) have a bmi ≥ 85th percentile; (2) are ≥8 and ≤12 years old at the beginning of treatment; (3) can read, write, and speak english, along with their caregiver; (4) plan to stay living in the local area during the study period; (5) have a consenting caregiver who can commit to all study procedures and provide reliable travel. exclusion criteria: - children who:(1) comorbid developmental/intellectual disability/traumatic brain injury/other identified condition known to substantially impact ef and/or weight management; (2) taking medication that is known to affect weight or appetite, (3) recent infection that may cause confounds of acute inflammation, (4) have an uncorrected visual or hearing impairment that would prohibit completion of cognitive testing, and (5) are unable to use an ipad with appropriate training for cognitive testing. the children without obesity (n=32) will have "normal-range" bmi scores (5th ≤bmi percentile\< 85th) but otherwise follow the same inclusion/exclusion criteria.

Keywords: pediatric obesity executive function behavioral intervention self-regulation acceptance-based
effects of tai chi chuan in patients after recent acute myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: this is a randomized clinical trial to assess the effects of tai chi chuan on blood pressure, respiratory muscle strength and functional capacity in patients after recent acute myocardial infarction.

background:patients with a recent myocardial infarction (mi) present a reduction in functional capacity expressed as a decrease in peak oxygen consumption (vo2 peak). the impact of a tai chi chuan (tcc) cardiac rehabilitation program for patients recovering from recent mi has yet to be assessed. our goal is to evaluate functional capacity after a tcc-based cardiac rehabilitation program in patients with recent mi. methods: a single-blind randomized clinical trial was conducted. the researchers who performed the tests were blinded to group allocation. between the 14th and 21st days after hospital discharge, all patients performed a cardiopulmonary exercise testing and a laboratory blood workup. mean age was similar (56 ± 9 years in the tcc group and 60 ± 9 years in the control group). patients allocated to the intervention group performed 3 weekly sessions of tcc beijin style for 12 weeks (n = 31). the control group participated in 3 weekly sessions of full-body stretching exercises (n = 30).

Eligibility criteria:
inclusion criteria: * recent acute myocardial infarction * age 45 and 75 years. * admission until 20 days after hospital discharge * with physical conditions for a cardiac rehabilitation program with exercise. exclusion criteria: * unstable angina * severe congestive heart failure * severe lung disease * altered response of blood pressure to stress
evaluation of an updated version of the program "blinkblink" for alleviation of dry eye symptoms induced by computer work

Conditions: Dry Eye Syndromes; Computer Vision Syndrome

Summary: the program "blinkblink" was developed to alleviate dry eye symptoms during prolonged computer work. this study aimed to show subjective and objective improvement of dry eye problems in a sample size of office workers

the increased use of digital devices and the resulting increase in near work has increased the prevalence of dry eye disease (ded). studies show that blink frequency reduced considerably during computer work, hence the tear film is spread less regularly over the anterior surface of the eye giving rise to an unstable tear film. this may lead to tired, dry eyes. the aim of this study was to observe if the tear film quality and dry eye symptoms may improve with the use of the computer animation program "blinkblink" during prolonged computer work. participating subjects test two versions of the program, whereby one version applies the animation in a much lower frequency, hence serving as a near placebo version. the testing order of the versions is randomized. the variables tested in this study are non-invasive tear film break up (nibut) and subjective dry eye symptoms with the ocular surface disease index (osdi) questionnaire.

Eligibility criteria:
inclusion criteria: * duration of computer work of at least six hours per day during at least four days per week * osdi score ≥ 18 * no active pathology on the anterior eye * snellen visual acuity of ≥ 0.8. exclusion criteria: * acute systemic disease * contact lens wear * asthenopia

Keywords: dry eye disease computer work computer vision syndrome
trial of montelukast in eosinophilic esophagitis

Conditions: Eosinophilic Esophagitis

Summary: evaluate clinical effectiveness of oral montelukast compared to placebo on prevention of dysphagia and food impaction in patients with ee. also evaluate tolerance and safety of oral montelukast in treatment of ee.

we will randomize in a double blind manner 60 consecutive consenting patients being evaluated at the three mayo clinic medical centers with ee to montelukast 20mg daily or placebo daily for six months? time. patients will be in remission after treatment with topical fluticasone therapy before enrollment. patients will fill out a validated dysphagia and side effect questionnaire before, during, and at the end of therapy.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * \> 14 eosinophils / hpf on biopsies from mid esophagus within the 6 months. * abnormal dysphagia questionnaire (question 1a yes, question 1c \>/= mild and question 2 \>/= less than once a week) prior to topical steroid treatment. this questionnaire has recently been validated. * normal dysphagia questionnaire after topical steroid treatment (having an answer of no to question 1a: have you had trouble swallowing, not associated with other cold symptoms? over the past two weeks since having completed the swallowed steroid treatment).
vagus nerve-guided robotic-assisted splenectomy and azygoportal disconnection

Conditions: Cirrhosis; Hypertension; Splenectomy; Robotic-assisted

Summary: this study aimed to evaluate whether vagus nerve-guided robotic-assisted splenectomy and azygoportal disconnection is effective and safe, and to determine whether a reduction in the incidence of postoperative complications of the digestive system improves postoperative quality of life compared with conventional robotic-assisted splenectomy and azygoportal disconnection.

after successful screening the cases of cirrhosis of liver irrespective of the etiology who have non tumor portal vein thrombosis will be enrolled. the baseline parameter will be recorded and the patient will be randomized into either interventional (vagus nerve-guided robotic-assisted splenectomy and azygoportal disconnection) or control (conventional robotic-assisted splenectomy and azygoportal disconnection) group. from postoperative day 3, all patients will receive 2.5 mg oral apixaban tablets (bristol-myers squibb, cruiserath, usa) twice daily for 6 months, low-molecular-weight heparin (cs bio, hebei, china) subcutaneously (4.100 iu/day) for 5 days, and 25 mg of oral dipyridamole (henan furen, henan, china) thrice daily for 3 months. at months 3 after operation, electron gastroscopy examination for delayed gastric emptying will be done for all patients. postoperative complications of the digestive system (including diarrhea, epigastric fullness, bloating, nausea, and vomiting), liver and renal function, and body weight will be recorded at the seventh day and months 3 after operation. then 3 months monitoring will be done in the both groups as per the primary or secondary outcome.

Eligibility criteria:
inclusion criteria: 1. a clinical, radiological or histologic diagnosis of cirrhosis of any etiology 2. splenomegaly with secondary hypersplenism 3. bleeding portal hypertension 4. no evidence of portal vein system thrombosis by ultrasound evaluation and angio-ct 5. informed consent to participate in the study exclusion criteria: 1. delayed gastric emptying 2. diarrhea 3. hepatocellular carcinoma or any other malignancy, 4. hypercoagulable state other than the liver disease related 5. drugs- oral contraceptives, anticoagulation or anti-platelet drugs. 6. child - pugh c 7. recent peptic ulcer disease 8. history of hemorrhagic stroke 9. pregnancy. 10. uncontrolled hypertension 11. human immunodeficiency virus (hiv) infection

Keywords: vagus nerve delayed gastric emptying cirrhosis hypertension robotic-assisted
study on chronic hepatitis c treatment with interferon alpha, ribavirin and amantadine in naive patients

Conditions: Chronic Hepatitis C

Summary: \* adding amantadine to standard anti-viral treatment can improve sustained response rates in patients with chronic hepatitis c

the cira-study is a double blind, placebo controlled, randomised, multicentre study in previously untreated patients suffering from chronic hepatitis c comparing double therapy, consisting of (peg-)interferon alpha 2b ((peg)intron-a®) and ribavirin (rebetol®), with triple therapy, consisting of (peg-)interferon alpha 2b, ribavirin and amantadine, for 52 weeks. follow-up is completed at week 104. 150 subjects per treatment group will be included. patients will be stratified before randomisation according to genotype (1 versus non-1). viral load will not be a discriminating factor. the aim is to investigate the efficacy of the adjunct amantadine to the currently used combination therapy with interferon alpha and ribavirin.

Eligibility criteria:
inclusion criteria: * anti-hcv positivity \>6 months * alt and/or ast elevation on at least once in the previous 6 months * positive hcv-rna * liver biopsy within one year before the start of therapy in non- cirrhosis. in the case of known cirrhosis, liver biopsy is not necessary * intention to be treated and participate treatment * obtained written informed consent exclusion criteria: * age \< 18 years * pregnancy or intention to get pregnant within the 12 months period of treatment and up to 6 months after discontinuation of therapy, no adequate contraception, lactation * men not practicing or willing to practice acceptable methods of contraception during the treatment period and up to 6 months after discontinuation of therapy * life expectancy \< 1 year * child pugh b or c (appendix iii) * creatinine \> 150 μmol/l or \> 1.70 mg/dl * haemoglobulin \< 6.5 mmol/l or \< 10.5 g/dl * white blood cell count \< 2,5 x 109/l, neutrophil \< 1,5 x 109/l * platelet count \< 70 x 109/l * hiv positivity * chemotherapy, systematical antiviral treatment during the 6 months prior to study entry * other serious disease (e.g. malignancy, uncontrolled myocardial disease or severe arrhythmias) * active uncontrolled psychiatric disorders and suicidal leanings * patients with a history of uncontrolled seizure or other significant cns dysfunction * any condition which in the opinion of the (co-)investigator might interfere with the evaluation of the study objectives

Keywords: chronic hepatitis c amantadine triple therapy
a study of ly3841136 in japanese participants with obesity or overweight

Conditions: Obesity; Overweight

Summary: the main purpose of this study is to learn about the side effects of ly3841136 alone and in combination with tirzepatide, when given to japanese participants with obese or overweight. blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. part a of the study will last about 28 weeks and may include up to 17 visits. part b of the study will last about 40 weeks and may include up to 29 visits.


Eligibility criteria:
inclusion criteria: * male or female participants who agree to contraception requirements * have a body mass index (bmi) within the range of 27 to 40 kg/m², inclusive * have had a stable weight for the 3 months exclusion criteria: * have a history of significant atopy (severe allergic manifestations), multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions * have a history or presence of psychiatric disorders, including a history of major depressive disorder or severe psychiatric disorders such as schizophrenia, bipolar disorder within the last 3 years * have been diagnosed with type 1 or type 2 diabetes mellitus * have a history of chronic medical conditions involving the heart, liver, or kidneys * have a history of any malignancy within the past 5 years * have a history or presence of a gi disorder * have had within the last 6 months, or plan to have during the study, a device-based or surgical treatment use for obesity * have been treated, or plan to be treated, with prescription medications or other non-approved drugs intended to promote weight loss, within 3 months prior to screening * for participants in part b, have previously received tirzepatide within 6 months prior to screening * for participants in part b, have a personal or family history of medullary thyroid carcinoma, or have multiple endocrine neoplasia syndrome type 2

Keywords: obesity disease metabolic disorders body weight loss
immunological and histological evaluation of specific immunotherapy with recombinant hypoallergenic derivative

Conditions: Allergic Rhinoconjunctivitis

Summary: this trial is performed for the immunological and histological evaluation of specific immunotherapy with an aluminium hydroxide-adsorbed recombinant hypoallergenic derivative of the major birch pollen allergen, rbet v1-fv

type i allergy is an immune-disorder which stems from the formation of ige antibodies against proteins and glycoproteins from plants, insects, animals and fungi, most of which are normally considered harmless. the cross-linking of specific ige antibodies on effector cells by allergens activates an immunological cascade leading to the symptoms of type i allergy including rhinitis, conjunctivitis, asthma, and anaphylactic shock. allergic rhinitis is the most common chronic atopic disease and is associated with considerable cost and co-morbidity. seasonal allergic rhinitis (sar), triggered by pollen from trees, grasses and weeds, is characterized by sneezing, nasal congestion, nasal itching, rhinorrhea, and pruritic, watery, red eyes. recombinant preparations offer various advantages over those based on natural allergen extracts. recombinant proteins can be produced in highly purified forms of pharmaceutical quality; proteins are molecularly defined thus ensuring product consistency and minimising problems related to allergen extract standardisation; preparations only include those proteins that are considered relevant for specific immunotherapy; the risk of contamination with other allergenic material is excluded; the whole production process can be designed to exclude any risk factors for the introduction of infectious agents; the relative dosages of individual components of a final preparation can be optimised to favour better clinical efficacy. allergy vaccination (av) mediates the immune response to allergen exposure by altering the th2 response in favour of a th1 t-cell response, increasing igg production and decreasing the production of inflammatory cytokines. rbet v1-fv is an av designed to enhance beneficial immune responses. the investigational product has demonstrated efficacy and good tolerability in one previous pivotal phase iii and two previous phase ii studies.

Eligibility criteria:
inclusion criteria: * positive spt * positive east * positive specific provocation test exclusion criteria: * serious chronic diseases * other perennial allergies

Keywords: specific immunotherapy sit scit recombinant type 1 - allergy
retraining attention to treat alcohol dependence and social anxiety

Conditions: Alcohol Drinking; Anxiety Disorders

Summary: the purpose of this research is to test a computerized intervention for people with co-occurring social anxiety and alcohol dependence. the intervention seeks to reduce symptoms by shifting attention away from alcohol-relevant and/or socially threatening cues. the investigators expect that participants receiving alcohol or anxiety training will experience reductions in those specific symptoms compared to participants in a control condition. the investigators also expect that participants receiving combined alcohol and anxiety training will show the largest reductions in alcohol and anxiety symptoms, relative to participants in any other condition.

alcohol use disorders (auds) and social anxiety disorder are disabling and chronic conditions. in spite of these common and significantly overlapping problems, insight into the mechanisms linking alcohol dependence and social anxiety symptoms is minimal, and there are not well established treatment guidelines for this population. in this study, the investigators seek to develop a computerized intervention for individuals with symptoms of social anxiety and alcohol dependence. the intervention attempts to reduce symptoms by shifting attention away from alcohol-relevant and/or socially threatening cues. the investigators expect that participants receiving alcohol or anxiety training will experience reductions in those specific symptoms compared to participants in a control condition. the investigators also expect that participants receiving combined alcohol and anxiety training will show the largest reductions in alcohol and anxiety symptoms, relative to participants in any other condition.

Eligibility criteria:
inclusion criteria: * current alcohol dependence * elevated social anxiety symptoms * willingness to consider cutting down on drinking exclusion criteria: * current psychosis * unmanaged manic symptoms * significant cognitive impairment * other drug use in past month * receiving cognitive behavioral therapy for alcohol use disorder or social anxiety * unable to read

Keywords: alcohol abuse alcohol dependence alcohol drinking social anxiety social phobia anxiety disorders
hybrid pet/ct in cancer patients

Conditions: Cancer

Summary: the purpose of the present study is to assess the role of hybrid pet/ct imaging diagnosis of active malignancy in cancer patients with rising tumor markers after treatment and in the diagnosis of primary tumor in patients with metastatic cancer of unknown origin. the clinical impact of pet/ct in the management and treatment of these two groups of cancer patients will be evaluated


Eligibility criteria:
inclusion criteria: * cancer patients in complete remission after treatment, with serial elevation of serum tumor markers and negative ct or other conventional imaging test. * patients with newly diagnosed metastatic cancer with unknown primary tumor * glucose levels below 150-200 * patient signed informed consent exclusion criteria: * pregnant or lactating women * patient unable or not willing to tolerate the test until its completion * one or more of the inclusion criteria is not fulfilled

Keywords: cancer patients